Home > Cardiology > ACC/WCC 2020 > Interventional Cardiology > PCI and CABG are equal in left main CAD

PCI and CABG are equal in left main CAD

Presented by
Dr D.W. Park, Asan Medical School, South Korea
Conference
ACC 2020
Trial
PRECOMBAT
Doi
https://doi.org/10.55788/4c9d2167
With a median follow-up of 11.3 years, the PRECOMBAT trial showed that percutaneous coronary intervention (PCI) with sirolimus-eluting stents was non-inferior to coronary-artery bypass grafting (CABG) among patients with severe left main disease.

Dr Duk-Woo Park (Asan Medical School, South Korea) presented the results of the open-label Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease (PRECOMBAT) trial [1]. PRECOMBAT was the first randomised study to compare PCI (n=300) with CABG (n=300) in patients with left main coronary artery disease. The results were simultaneously published online in Circulation [2].

At 10 years, there was no difference between the 2 groups; the primary composite endpoint of all-cause mortality, myocardial infarction, stroke, or ischaemia-driven revascularisation occurred in 29.8% of patients treated with PCI and 24.7% of patients in the CABG surgery group (HR 1.25; 95% CI 0.93-1.69). However, looking at individual components, the rate of revascularisation was significantly higher in patients treated with PCI (16.1% vs 8.0%; HR 1.98; 95% CI 1.21-3.21).

The study was not powered for clinical outcomes at 10 years. Dr Park cautioned that the results should be considered hypothesis-generating only and pointed out that the open-label nature of this study may have influenced some of the non-fatal outcomes. Further research is warranted for data concerning extended follow-up.


    1. Park S-J, et al. Abstract 410-14. ACC/WCC 28-30 March 2020.
    2. Park DW, et al. Circulation. 2020. DOI:10.1161/CIRCULATIONAHA.120.046039.




Posted on